Dr Toni Choueiri talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the biomarker analysis from the JAVELIN Renal 101 trial which observed avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).
He reports that PD-L1 as a biomarker was a negative prognostic indicator in patients who received sunitinib and didn't impact the benefit from avelumab plus axitinib.
Dr Choueiri explains however that high CD8 was associated with high progression free survival in the combination arm and the opposite in patients who received sunitinib.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
